Articles by Laura Litwin
A recent study reviewed global disparities in gastric cancer screening, finding limited research about screening feasibility.
A recent study showed evidence that HBV infection facilitates drug resistance in cancer treatment medications.
A recent analysis reviewed patient-level data to identify the relationship between pathological response and relapse.
A recent study compared first-line chemotherapy, as the standard of care for PDAC, with other treatment options.
The phase III study found that regorafenib improved overall survival in patients with refractory advanced gastric cancer.
Study participants were administered nadunolimab with a standard dose of gemcitabine and nab-paclitaxel (GN) every two weeks.
FDA approval of the first and only CLDN18.2-targeted treatment follows two successful phase III clinical trials.
630 Madison Ave.
Manalapan, NJ 07726
About Column
Contribute Column
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.